Stay updated on Pembrolizumab in Lymphoma Subtypes Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Subtypes Clinical Trial page
- CheckyesterdayChange DetectedVersion bump from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange Detected- Added inclusion criterion: B-cell lymphoma unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.SummaryDifference0.0%

- Check30 days agoChange DetectedA new revision, v3.5.0, has been added; the previous revision, v3.4.3, has been removed.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page now displays Revision: v3.4.3 and no longer shows Revision: v3.4.2.SummaryDifference0.0%

- Check66 days agoChange DetectedPage updated to Revision: v3.4.2. The previous funding-status notice (v3.4.1) and related operating-status messaging have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check73 days agoChange DetectedAdded a government funding lapse notice and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Lymphoma Subtypes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.